Details

Autor(en) / Beteiligte

• Loinaz, Carmelo
• Marcacuzco, Alberto
• Fernández‐Ruiz, Mario
• Caso, Oscar
• Cambra, Félix
• San Juan, Rafael
• Justo, Iago
• Calvo, Jorge
• García‐Sesma, Alvaro
• Manrique, Alejandro
• Pérez‐Jacoiste Asín, María Asunción
• Folgueira, María Dolores
• Aguado, José María
• Lumbreras, Carlos

Titel

Varied clinical presentation and outcome of SARS‐CoV‐2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain

Ist Teil von

• Transplant infectious disease, 2020-10, Vol.22 (5), p.e13372-n/a

Ort / Verlag

Denmark: Wiley Subscription Services, Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Wiley Online Library Journals【キャンパス外アクセス可】

Beschreibungen/Notizen

• Background Which are the consequences of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in liver transplant (LT) recipients? Methods We attempted to address this question by reviewing our single‐center experience during the first 2 months of the pandemics at a high incidence area. Results Nineteen adult patients (5 females) were diagnosed by May 5, 2020. Median age was 58 (range 55‐72), and median follow‐up since transplantation was 83 (range 20‐183) months. Cough (84.2%), fever (57.9%), and dyspnea (47.4%) were the most common symptoms. Thirteen patients (68.4%) had pneumonia in x‐ray/CT scan. Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon β in 2 cases each. Immunomodulatory therapy with tocilizumab was used in 2 patients. Immunosuppression (IS) was halted in one patient and modified in only other two due to potential drug interactions. Five (26.3%) patients were managed as outpatient. Two patients (10.5%) died, 10 (52.6%) were discharged home, and 2 (10.5%) were still hospitalized after a median follow‐up of 41 days from the onset of symptoms. Baseline IS regimen remained unchanged in all surviving recipients, with good liver function. Conclusions Our preliminary experience shows a broad spectrum of disease severity in LT patients with COVID‐19, with a favorable outcome in most of them without needing to modify baseline IS.